Baraclude


Also found in: Dictionary, Wikipedia.
Related to Baraclude: hepatitis B

entecavir

Baraclude

Pharmacologic class: Guanosine nucleoside analogue

Therapeutic class: Antiviral

Pregnancy risk category C

FDA Box Warning

• Drug may cause lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) when used alone or in combination with antiretrovirals.

• Severe acute hepatitis B exacerbations have occurred in patients who discontinued anti-hepatitis B therapy, including entecavir. Monitor hepatic function for at least several months after discontinuation. If appropriate, initiate anti-hepatitis B therapy.

• When used to treat chronic hepatitis B, drug may cause human immunodeficiency virus (HIV) resistance to HIV nucleoside reverse transcriptase inhibitors in patients with untreated HIV infection. Therapy isn't recommended for HIV/hepatitis B virus (HBV) co-infected patients except those also receiving highly active antiretroviral therapy.

Action

Competes with natural substrate deoxyguanosine triphosphate to inhibit HBV polymerase (reverse transcriptase)

Availability

Oral solution: 0.05 mg/ml

Tablets: 0.5 mg, 1 mg

Indications and dosages

Chronic HBV infection with evidence of active viral replication and either persistent serum transaminase elevations or histologically active disease

Adolescents and adults ages 16 and older: In nucleoside-treatment-naïve patients with compensated liver disease, 0.5 mg P. O. once daily. In patients with a history of hepatitis B viremia while receiving lamivudine or known lamivudine or telbivudine resistance mutations rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L, or patients with decompensated liver disease, 1 mg P.O. once daily.

Dosage adjustment

• Creatinine clearance below 50 ml/minute

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:
• liver transplant recipients who are receiving or have received immunosuppressants that may affect renal function
• elderly patients
• pregnant or breastfeeding patients
• children younger than age 16.

Administration

• Administer at least 2 hours before or after a meal.

Adverse reactions

CNS: headache, dizziness, fatigue

GI: nausea, diarrhea, dyspepsia, increased GI enzymes

Hematologic: hematuria

Hepatic: HBV exacerbation, severe hepatomegaly

Metabolic: glycosuria,lactic acidosis

Interactions

Drug-drug.Drugs that reduce renal function or compete for active tubular secretion: increased blood levels of either drug

Drug-diagnostic tests.Alanine aminotransferase, amylase, aspartate aminotransferase, lipase, glucose, serum creatinine, total bilirubin: increased

Patient monitoring

• Monitor renal function before and during therapy, especially in liver transplant recipients who are receiving or have received immunosuppressants that may affect renal function.

Monitor liver function closely for evidence of HBV exacerbation for at least several months after drug discontinuation.

Monitor for lactic acidosis (associated with nucleoside analogues).

Patient teaching

• Instruct patient to take drug on empty stomach (at least 2 hours before or after a meal).

Teach patient about signs and symptoms of lactic acidosis and importance of contacting prescriber if these occur.

Instruct patient to immediately report worsening symptoms, such as increased yellowing of skin or eyes, dark urine, or fatigue.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

entecavir

(en-tek-aveer) ,

Baraclude

(trade name)

Classification

Therapeutic: antivirals
Pharmacologic: nucleoside analogues
Pregnancy Category: C

Indications

Chronic hepatitis B infection with evidence of active disease.

Action

Phosphorylated intracellularly to active form which acts as an analogue of guanosine, interfering with viral DNA synthesis.

Therapeutic effects

Decreased hepatic damage due to chronic hepatitis B infection.

Pharmacokinetics

Absorption: Well absorbed following oral administration.
Distribution: Extensive tissue distribution.
Metabolism and Excretion: 62–73% excreted unchanged by kidneys.
Half-life: Plasma—128–149 hr; intracellular—15 hr.

Time/action profile (blood levels)

ROUTEONSETPEAKDURATION
POrapid0.5–1 hr24 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Lactation: Potential for serious adverse effects in infant.
Use Cautiously in: Renal impairment (dose reduction recommended if CCr <50 mL/min;Liver transplant recipients (careful monitoring of renal function recommended);Patients coinfected with HIV (unless receiving highly active antiretroviral therapy; at ↑ risk for resistance); Obstetric: Use only if clearly needed, considering benefits and risks; Pediatric: Safety not established in children <16 yr; Geriatric: ↑ risk of toxicity due to age-related ↓ in renal function.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness
  • fatigue
  • headache

Gastrointestinal

  • hepatomegaly (with steatosis)
  • dyspepsia
  • nausea

Fluid and Electrolyte

  • lactic acidosis (life-threatening)

Dermatologic

  • alopecia
  • rash

Interactions

Drug-Drug interaction

Concurrent use of drugs which may impair renal function may ↑ blood levels and risk of toxicity.

Route/Dosage

Oral (Adults and Children >16 yr) 0.5 mg once daily; history of lamivudine resistance—1 mg once daily.

Renal Impairment

Oral (Adults and Children >16 yr) CCr 30–50 mL/min—0.25 mg once daily, history of lamivudine resistance—0.5 mg once daily; CCr 10– <30 mL/min—0.15 mg once daily, history of lamivudine resistance—0.3 mg once daily; CCr <10 mL/min—0.05 mg once daily, history of lamivudine resistance—0.1 mg once daily.

Availability (generic available)

Tablets: 0.5 mg, 1 mg
Oral solution orange: 0.05 mg/mL

Nursing implications

Nursing assessment

  • Monitor signs of hepatitis (jaundice, fatigue, anorexia, pruritus) during and for several months following discontinuation of therapy. Exacerbations may occur when therapy is discontinued.
  • May cause lactic acidosis and severe hepatomegaly with steatosis. Monitor patient for signs (↑ serum lactate levels, elevated liver enzymes, liver enlargement on palpation). Suspend therapy if clinical or laboratory signs occur.
  • Lab Test Considerations: Monitor liver function closely during and for several months following discontinuation of therapy. May cause ↑ AST, ALT, bilirubin, amylase, lipase, creatinine, and serum glucose. May cause ↓ serum albumin.

Potential Nursing Diagnoses

Risk for infection (Indications)
Noncompliance (Patient/Family Teaching)

Implementation

  • Oral: Administer on an empty stomach at least 2 hr before or after a meal. Oral solution is ready to use and should not be diluted or mixed with water or any other liquid. Hold spoon in a vertical position and fill gradually to mark corresponding to the prescribed dose. Rinse dosing spoon with water after each daily dose. Store in outer carton at room temperature. After opening, solution can be used until expiration date on bottle.

Patient/Family Teaching

  • Instruct patient to read the Patient Information with each refill and to take entecavir as directed. Take missed doses as soon as possible unless almost time for next dose. Do not run out of entecavir; get more when supply runs low. Do not double doses. Emphasize the importance of compliance with full course of therapy, not taking more than the prescribed amount, and not discontinuing without consulting health care professional. Inform patient that hepatitis exacerbation may occur upon discontinuation of therapy. Caution patient not to share medication with others.
  • Inform patient that entecavir does not cure HBV disease, but may lower the amount of HBV in the body, lower the ability of HBV to multiply and infect new liver cells, and may improve the condition of the liver. Entecavir does not reduce the risk of transmission of HBV to others through sexual contact or blood contamination. Caution patient to use a condom during sexual contact and avoid sharing needles or donating blood to prevent spreading HBV to others.
  • Advise patient to notify health care professional promptly if signs of lactic acidosis (weakness or tiredness; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in arms or legs; dizziness, fast or irregular heartbeat) or hepatotoxicity (jaundice, dark urine, light-colored bowel movements, anorexia, nausea, lower stomach pain) occur.
  • May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Discuss the possibility of hair loss with patient. Explore methods of coping.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.
  • Emphasize the importance of regular follow-up exams and blood tests to determine progress and monitor for side effects.

Evaluation/Desired Outcomes

  • Decreased hepatic damage due to chronic hepatitis B infection.

Baraclude

a trademark for entecavir.
Mentioned in ?
References in periodicals archive ?
Baraclude is an anti-viral action drug for treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases or histologically active disease.
Discovered by Bristol-Myers Squibb, BARACLUDE (entecavil) is an oral nucleoside analogue that selectivity inhibits HBV polymerase.
BARACLUDE is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Drug-delivery, fluid infusion, nutrition formulations, preparations, diagnostic contrast, preparations for the treatment of chronic hepatitis - type c and BARACLUDE
The black box warning for entecavir now includes the statement that "limited clinical experience suggests there is a potential for the development of resistance" to HIV nucleoside reverse transcriptase inhibitors "if Baraclude is used to treat chronic hepatitis B virus infection in patients with HIV infection that is not being treated.
Teva Pharmaceutical Industries Limited Research Reports On September 4, 2014, Teva Pharmaceuticals Industries Limited (Teva) announced the launch of the generic equivalent to Baraclude (Entecavir) Tablets, 0.
A Study provides further efficacy and safety data for BARACLUDE in this special patient population-
The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.
PCTs are now required to make funding available for Baraclude for patients prescribed it by their specialist.
BARACLUDE is currently indicated for the treatment of chronic hepatitis B (CHB) in adults with evidence of active viral replication and either evidence of persistent elevations in aminotransferases (ALT or AST), or histologically active disease.
Our study forecasts individual revenues of 10 top products: -- Baraclude -- Zeffix -- Hepsera -- Viread -- Tyzeka -- Engerix-B/Havrix/Twinrix/Fendrix -- Pegasys -- Incivek -- PegIntron -- Victrelis.